Morgan Stanley analyst Craig Hettenbach lowered the firm’s price target on Veeva to $160 from $181 and keeps an Underweight rating on the shares. After a correction in the stock, there’s only modest downside to the firm’s new price target, the analyst tells investors in a research note. The firm added that it still sees poor risk/reward skew and expects the company to underperform due to a downward bias to estimates and new competitive risks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VEEV:
- Doximity price target raised to $21 from $20 at BofA
- Veeva price target lowered to $205 from $211 at Stifel
- Veeva price target lowered to $232 from $242 at Baird
- Veeva price target lowered to $200 from $220 at BofA
- Veeva price target lowered to $220 from $250 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com